

## Table of Contents

### Guest Editors for this issue:

**James Maloney, MD**  
Associate Professor of Pulmonary and  
Critical Care Medicine  
University of Colorado Health Sciences Center  
Denver, Colorado

**Todd Bull, MD**  
Assistant Professor  
Division of Pulmonary Sciences and  
Critical Care Medicine  
University of Colorado Health Sciences Center  
Denver, Colorado

- 208 Profile: David Badesch, MD
- 217 International Corner
- 220 CME Section Overview
- 222 Evidence-based Medical  
Management of Pulmonary  
Hypertension 2008: Review of  
Updated 2007 ACCP Guidelines
- 228 Phase 2 and 3 Clinical Trials  
in Pulmonary Arterial  
Hypertension
- 235 Combination Therapies in  
Pulmonary Arterial  
Hypertension
- 243 CME Post-Test
- 245 Guidelines for the Prevention  
of Central Venous Catheter-  
Related Bloodstream Infections  
with Prostanoid Therapy for  
Pulmonary Arterial Hypertension
- 249 Pulmonary Hypertension  
Roundtable Discussion

### Publisher

Pulmonary Hypertension Association  
Michael D. McGoon, MD, *Chair of the Board*  
Rino Aldrighetti, *President*  
Rachel Pokorney, *Associate Director of Medical Services*

### PHA Office

Pulmonary Hypertension Association  
801 Roeder Rd. Suite 400  
Silver Spring, MD 20910-4496  
301-565-3004, 301-565-3994 (fax)  
[www.phassociation.org](http://www.phassociation.org)

© 2008 by Pulmonary Hypertension Association. All rights reserved. None of the contents may be reproduced in any form whatsoever without the written permission of PHA.

ISSN: 1933-088X (print); 1933-0898 (online)

### Editorial Offices

*Advances in Pulmonary Hypertension*, DataMedica,  
P.O. Box 1688, Westhampton Beach, NY 11978  
Tel (631) 288-7733 Fax (631) 288-7744  
E-mail: [sbelsonchapman@aol.com](mailto:sbelsonchapman@aol.com)

*Advances in Pulmonary Hypertension* is circulated to cardiologists, pulmonologists, rheumatologists, and other selected physicians by the Pulmonary Hypertension Association. The contents are independently determined by the Editor and the Editorial Advisory Board. All past issues of the journal are available at: [www.PHAssociation.org/Medical/Advances\\_in\\_PH/](http://www.PHAssociation.org/Medical/Advances_in_PH/)

### Cover Image

The key to effective therapy is to unlock the benefits of new options and combinations, as suggested by these images. (Copyright, Fotosearch, 2008)

## Editor's Memo

# Introducing CME Credit– and More Dynamic Content



This first-quarter 2008 issue marks the first time *Advances in Pulmonary Hypertension* will be offering continuing medical education (CME) credit. We are pleased to make this service available through the University of Michigan Medical School. Upon completing the questions related to each topic, readers will be able to claim up to 2.0 hours of CME credit while learning the latest about pulmonary hypertension. This issue also kicks off our new International Corner, with an initial commentary by Adam Torbicki,

MD, PhD, of Warsaw, Poland. His thoughts on the fourth-quarter 2007 issue are provided in English and Polish.

It is hoped that these exciting additions will help further the study of pulmonary hypertension across the globe. Working toward this goal, I hope you will join me at PHA's Eighth International PH Conference and Scientific Sessions this June in Houston, Texas. With more than 60 scientific and clinical posters, four presentations by distinguished investigators, and sessions for patients and family members, this Conference is unique and not to be missed.

James Maloney, MD, the lead Guest Editor for this issue, with the assistance of Todd Bull, MD, superbly edited the leading-edge content covering medical management, clinical trials, and combination therapies. The first article by Jeremiah Depta, MD, and Richard Krasuski, MD, reviews the recently updated American College of Chest Physicians guidelines on medical management of pulmonary arterial hypertension. The article by Zeenat Safdar, MD, covers ongoing phase 2 and phase 3 clinical trials that are likely to be completed soon and will potentially provide evidence for new treatment options. Ioana R. Preston, MD, a member of the *Advances in Pulmonary Hypertension* Editorial Board, covers the ever-changing and often contested spectrum of combination drug therapy for pulmonary arterial hypertension. This paper is a comprehensive summary of available and emerging evidence, mostly in support of using at least two different PAH drugs for additive and perhaps synergistic effects on the pulmonary circulation.

Finally, a Roundtable Discussion led by Karen Fagan, MD, covers an increasingly important consideration, namely, the use of pulmonary arterial hypertension therapy in a broader group of patients than have been studied to date. This has important implications for the patients in question, and also for future patient groups to be targeted for treatment with PAH-specific drugs. Panel members included Kamal K. Mubarak, MD, Zeenat Safdar, MD, Aaron Waxman, MD, PhD, and Roham T. Zamanian, MD.

**Ronald J. Oudiz, MD**  
Editor-in-Chief

## Guest Editor's Commentary

This issue of the journal offers a simultaneous look at our past and future in the search for effective treatments for pulmonary arterial hypertension. Thanks to an ever-increasing number of randomized controlled trials, we now have the luxury of an evidence-based approach to therapy. Yet, although these treatment paradigms have improved patients' symptoms and outcomes, it is undeniably clear that we still have far to go. Combination therapy for pulmonary arterial hypertension provides a new and exciting approach with a growing body of evidence supporting its efficacy. At the same time a number of novel agents are working their way through early phase trials. It is truly an exciting time in the treatment of pulmonary arterial hypertension as we attempt to unlock the mysteries of this disease.—**James Maloney, MD**

## Editorial Advisory Board

### Editor-in-Chief

#### Ronald J. Oudiz, MD

Associate Professor of Medicine  
UCLA School of Medicine  
Director, Liu Center for Pulmonary  
Hypertension  
Division of Cardiology  
Los Angeles Biomedical Research  
Institute at Harbor-UCLA  
Medical Center  
Torrance, California

### Immediate Past Editor

#### Vallerie V. McLaughlin, MD

Associate Professor of Medicine  
Director, Pulmonary Hypertension  
Program  
University of Michigan Health System  
Ann Arbor, Michigan

### Editor-in-Chief Elect

#### Richard Channick, MD

Professor of Clinical Medicine  
Pulmonary and Critical Care Division  
University of California, San Diego  
Medical Center  
San Diego, California

### Associate Editors

#### Erika Berman Rosenzweig, MD

Assistant Professor of Pediatrics  
Department of Pediatrics  
Columbia College of Physicians  
and Surgeons  
New York, New York

#### Todd Bull, MD

Associate Professor of Medicine  
Medical Director, ICU Anshutz  
Inpatient Pavilion  
Division of Pulmonary Sciences and  
Critical Care Medicine  
University of Colorado Health Sciences  
Center  
Denver, Colorado

#### Robert Schilz, DO, PhD

Medical Director of Lung Transplantation  
and Pulmonary Vascular Disease  
University Hospital of Cleveland  
Case Western Reserve University  
Cleveland, Ohio

### Editorial Board

#### Teresa De Marco, MD

Director, Heart Failure and  
Pulmonary Hypertension Program  
University of California, San Francisco  
San Francisco, California

#### Eli Gabbay, MD

Associate Professor  
University of Western Australia  
School of Medicine and Pharmacology  
Medical Director, Advanced Lung Disease  
and Pulmonary Vascular Unit  
Royal Perth Hospital  
Perth, Australia

#### Kristin Highland, MD

Assistant Professor  
Division of Pulmonary and Critical  
Care Medicine  
Director, Pulmonary Hypertension Clinic  
Medical University of South Carolina  
Charleston, South Carolina

#### Omar Minai, MD

Staff Physician  
Cleveland Clinic  
Cleveland, Ohio

#### Myung H. Park, MD

Director, Pulmonary Vascular  
Diseases Program  
University of Maryland School of  
Medicine  
Baltimore, Maryland

#### Ioana Preston, MD

Assistant Professor of Medicine  
Tufts-New England Medical Center  
Boston, Massachusetts

#### Zeenat Safdar, MD

Assistant Professor of Medicine  
Department of Medicine,  
Pulmonary & Critical Care Section  
Pulmonary Hypertension Center  
Baylor College of Medicine  
Houston, Texas

#### Rajan Saggat, MD

Assistant Professor of Medicine  
Division of Pulmonary and Critical Care  
Medicine and Hospitalists  
David Geffen School of  
Medicine at UCLA  
Los Angeles, California

#### Francisco Soto, MD

Assistant Professor  
Director, Pulmonary Hypertension  
Program  
Medical College of Wisconsin  
Milwaukee, Wisconsin

#### Fernando Torres, MD

Director, Pulmonary Hypertension  
Program  
UT Southwestern Medical Center  
Dallas, Texas

### Program Description

The mission of *Advances in Pulmonary Hypertension* is to serve as the premiere forum for state of the art information regarding diagnosis, pathophysiology, and treatment of pulmonary hypertension. The 2003 Venice revision of the World Health Organization Classification serves as a guide to categories of pulmonary hypertension addressed by the Journal. While focusing on WHO Group I PAH, the other categories (Group II, Left heart disease; Group III, Associated with lung disease and/or hypoxemia; Group IV, Thrombotic and/or Embolic Disease; Group V, Miscellaneous) are also addressed. This mission is achieved by a combination of invited review articles, Roundtable discussions with panels consisting of international experts in PH, and original contributions. In addition, a special section entitled "Profiles in Pulmonary Hypertension" recognizes major contributors to the field and serves as an inspiring reminder of the rich and collegial history of dedication to advancing the field.

### Objectives

- Provide up-to-date information regarding diagnosis, pathophysiology, and treatment of pulmonary hypertension.
- Serve as a forum for presentation and discussion of important issues in the field, including new paradigms of disease understanding and investigational trial design.
- Recognize and preserve the rich history of individuals who have made major contributions to the field via dedication to patient care, innovative research, and furthering the mission of the PH community to cure pulmonary hypertension.

## The Scientific Leadership Council of the Pulmonary Hypertension Association

The scientific program of the Pulmonary Hypertension Association is guided by the association's Scientific Leadership Council. The Council includes the following health care professionals:

#### David B. Badesch, MD

SLC Chair  
University of Colorado Health  
Sciences Center  
Denver, Colorado

#### Robyn J. Barst, MD

SLC Immediate Past Chair  
Columbia-Presbyterian Medical  
Center Babies Hospital  
New York, New York

#### Vallerie V. McLaughlin, MD

SLC Vice-Chair  
University of Michigan Health System  
Ann Arbor, Michigan

#### Raymond L. Benza, MD

University of Alabama Health System  
Birmingham, Alabama

#### Todd Bull, MD

University of Colorado Health  
Sciences Center  
Denver, Colorado

#### Richard N. Channick, MD

UCSD Medical Center  
San Diego, California

#### C. Gregory Elliott, MD

LDS Hospital  
University of Utah School of Medicine  
Salt Lake City, Utah

#### Karen A. Fagan, MD

Chair, Scientific Sessions Committee  
University of South Alabama  
College of Medicine  
Mobile, Alabama

#### Adaani Frost, MD

Baylor College of Medicine  
Houston, Texas

#### John Granton, MD

Toronto General Hospital  
Toronto, Canada

#### Nazzareno Galiè, MD

Institute of Cardiology  
University of Bologna  
Bologna, Italy

#### Nicholas S. Hill, MD

Division of Pulmonary, Critical Care  
and Sleep Medicine  
Tufts-New England Medical Center  
Boston, Massachusetts

#### Marius Hoeper, MD

Hannover Medical school  
Hannover, Germany

#### Dunbar Ivy, MD

University of Colorado Health  
Sciences Center  
Denver, Colorado

#### Zhi-Cheng Jing, MD

Fu wai Heart Hospital  
Beijing, China

#### Anne M. Keogh, MD

St. Vincent's Public Hospital  
Sydney, Australia

#### Michael J. Krowka, MD

Chair, Medical Sessions Committee  
Mayo Clinic  
Rochester, Minnesota

#### James E. Loyd, MD

Vanderbilt University Medical Center  
Nashville, Tennessee

#### Michael D. McGoon, MD

Chair, PHA Board of Trustees  
Pulmonary Hypertension Clinic  
Mayo Clinic  
Rochester, Minnesota

#### Srinivas Murali, MD

Chair, Education Committee  
Allegheny General Hospital  
Pittsburgh, Pennsylvania

#### John H. Newman, MD

Chair, Research Committee  
Vanderbilt Medical School  
Nashville, Tennessee

#### Ronald J. Oudiz, MD

Liu Center for Pulmonary Hypertension  
Los Angeles Biomedical Research  
Institute  
Harbor-UCLA Medical Center  
Torrance, California

#### Marlene Rabinovitch, MD

Stanford University School of Medicine  
Stanford, California

#### Erica Berman-Rosenzweig, MD

Columbia-Presbyterian Medical Center  
New York, New York

#### Ivan M. Robbins, MD

Vanderbilt University  
Nashville, Tennessee

#### Julio Sandoval, MD

Cardiopulmonary Department  
National Institute of Cardiology  
of Mexico  
Tlalpan, Mexico

#### Richard Silver, MD

Medical University of South Carolina  
Charleston, South Carolina

#### Victor F. Tapson, MD

Division of Pulmonary and Critical  
Care Medicine  
Duke University Medical Center  
Durham, North Carolina

### Liaisons

#### Joy Beckmann, RN, MSN

Chair, PH Resource Network  
Torrance, California

#### Joanne Sperando Schmidt

Patient Liaison

### Emeritus Members

#### Bruce H. Brundage, MD

St. Charles Medical Center-Bend  
Bend, Oregon

#### Alfred P. Fishman, MD

University of Pennsylvania Health  
System  
Philadelphia, Pennsylvania

*The Mission of the Scientific Leadership Council is to provide medical and scientific guidance and support to the PHA by:*

- Developing and disseminating knowledge for diagnosing and treating pulmonary hypertension
- Advocating for patients with pulmonary hypertension
- Increasing involvement of basic and clinical researchers and practitioners

More information on PHA's Scientific Leadership Council and associated committees can be found at:  
[www.PHAssociation.org/SLC/](http://www.PHAssociation.org/SLC/)